A New Biomarker Tool for Risk Stratification in " de novo " Acute Heart Failure (OROME).

Autor:	Agra-Bermejo RM; Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.; Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain., Cacho-Antonio C; Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain., Gonzalez-Babarro E; Cardiovascular Area, Hospital Montecelo, Pontevedra, Spain., Rozados-Luis A; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Couselo-Seijas M; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Gómez-Otero I; Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.; Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain., Varela-Román A; Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.; Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain., López-Canoa JN; Cardiovascular Area, Hospital Montecelo, Pontevedra, Spain.; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Gómez-Rodríguez I; Cardiovascular Area, Hospital Montecelo, Pontevedra, Spain., Pata M; Biostatech, University of Santiago de Compostela, Santiago de Compostela, Spain., Eiras S; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain.; Traslational Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., González-Juanatey JR; Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.; Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; CIBERCV: Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in physiology [Front Physiol] 2022 Jan 13; Vol. 12, pp. 736245. Date of Electronic Publication: 2022 Jan 13 (Print Publication: 2021).
DOI:	10.3389/fphys.2021.736245
Abstrakt:	Background: Inflammation is one of the mechanisms involved in heart failure (HF) pathophysiology. Thus, the acute phase reactant protein, orosomucoid, was associated with a worse post-discharge prognosis in de novo acute HF (AHF). However, the presence of anti-inflammatory adipokine, omentin, might protect and reduce the severity of the disease. We wanted to evaluate the value of omentin and orosomucoid combination for stratifying the risk of these patients. Methods and Results: Two independent cohorts of patients admitted for de novo AHF in two centers were included in the study ( n = 218). Orosomucoid and omentin circulating levels were determined by ELISA at discharge. Patients were followed-up for 317 (3-575) days. A predictive model was determined for the primary endpoint, death, and/or HF readmission. Differences in survival were evaluated using a Log-rank test. According to cut-off values of orosomucoid and omentin, patients were classified as UpDown (high orosomucoid and low omentin levels), equal (both proteins high or low), and DownUp (low orosomucoid and high omentin levels). The Kaplan Meier determined a worse prognosis for the UpDown group (Long-rank test p = 0.02). The predictive model that includes the combination of orosomucoid and omentin groups (OROME) + NT-proBNP values achieved a higher C-index = 0.84 than the predictive model with NT-proBNP (C-index = 0.80) or OROME (C-index = 0.79) or orosomucoid alone (C-index = 0.80). Conclusion: The orosomucoid and omentin determination stratifies de novo AHF patients into the high, mild, and low risk of rehospitalization and/or death for HF. Its combination with NT-proBNP improves its predictive value in this group of patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Agra-Bermejo, Cacho-Antonio, Gonzalez-Babarro, Rozados-Luis, Couselo-Seijas, Gómez-Otero, Varela-Román, López-Canoa, Gómez-Rodríguez, Pata, Eiras and González-Juanatey.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu